Top Markets
#1 Black Phoenix Black Phoenix +165.81%
#2 Islamic Coin Islamic Coin +158.09%
#3 Glidr Glidr +84.34%
#4 Acurast Acurast +25.47%
#5 Cryptopia Cryptopia +20.92%
#6 Quantum Resistant Ledger Quantum Resistant Ledger +19.43%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.69%
#8 Test Test +15.09%
#9 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +11.31%
#10 DOVU DOVU +9.07%
Coin of the day
Black Phoenix Black Phoenix
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
ARYx Therapeutics, Inc. ARYx Therapeutics, Inc.

ARYx Therapeutics, Inc.

ARYX
Classifica tra le azioni #41544
Based in Fremont, California, and established in 1997, ARYx Therapeutics, Inc.... Based in Fremont, California, and established in 1997, ARYx Therapeutics, Inc. is dedicated to discovering and advancing innovative treatments, primarily focusing on widespread, chronic conditions addressable with oral medications. The company utilizes its unique RetroMetabolic Drug Design technology to engineer distinctive molecular compounds that maintain the therapeutic effectiveness of their original counterparts. Its clinical development portfolio includes several promising candidates: Tecarfarin (ATI-5923): An oral anticoagulant currently in Phase III clinical trials, aimed at preventing hazardous blood clots in at-risk patients. Budiodarone (ATI-2042): An oral antiarrhythmic agent undergoing Phase IIb development for managing atrial fibrillation, a form of irregular heart rhythm. ATI-7505: An oral prokinetic agent in Phase IIb clinical development, targeting various gastrointestinal issues such as chronic constipation, gastroparesis, functional dyspepsia, irritable bowel syndrome with constipation, and gastroesophageal reflux disease. ATI-9242: An antipsychotic agent progressing through Phase I clinical trials for the treatment of schizophrenia and other psychiatric conditions. Additionally, ARYx Therapeutics is conducting early-stage research on ATI-20,000 for metabolic disorders and ATI-24,000 for gastrointestinal ailments.
Prezzo delle azioni
$0.0005
Ultima sincronizzazione: 2026-08-11
Capitalizzazione di mercato
$16.73K
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia ARYx Therapeutics, Inc. (ARYX)

Categoria

Healthcare
Rapporto P/B per ARYx Therapeutics, Inc. (ARYX)
Rapporto P/B al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di ARYx Therapeutics, Inc., il rapporto P/B attuale (TTM) è 0. Alla fine del 2026, era pari a 0.
Storico del rapporto P/B per ARYx Therapeutics, Inc. da 2026 a 2026
Rapporto P/B alla fine di ogni anno
Anno Rapporto P/B Cambia
Non abbastanza dati per le date fornite.
Rapporto P/B per aziende simili o concorrenti
Azienda Rapporto P/B Differenza del rapporto P/B Il paese
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
 - -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
 - -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
 - -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
 - -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 5.7207 -
IN